Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab

BACKGROUND: Up to 30% of patients with food allergies have clinical reactivity to more than one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under investigation. Pilot data have shown that omalizumab may hasten the ability to tolerate over 4 g of food allergen prot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bégin, Philippe, Dominguez, Tina, Wilson, Shruti P, Bacal, Liane, Mehrotra, Anjuli, Kausch, Bethany, Trela, Anthony, Tavassoli, Morvarid, Hoyte, Elisabeth, O’Riordan, Gerri, Blakemore, Alanna, Seki, Scott, Hamilton, Robert G, Nadeau, Kari C
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2014
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3936817/
https://ncbi.nlm.nih.gov/pubmed/24576338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1710-1492-10-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados